PharmaBlock Group
Qihai Xu is currently working as a Principle Scientist and Project Lead at PharmaBlock Group since April 2023. Prior to this, they served as a Senior Chemist II at Adesis, Inc. from February 2022 to April 2023 and as a Senior Chemist I from January 2017 to February 2022. Qihai also worked as a Postdoctoral Scientist at The Janssen Pharmaceutical Companies of Johnson & Johnson from April 2015 to January 2017, as a Postdoctoral Associate at the University of North Carolina at Chapel Hill from January 2013 to April 2015, as a Postdoctoral Associate at UCLA from October 2007 to January 2013, and as an Associate Professor at Shanghai Institute of Organic Chemistry, CAS from July 2004 to September 2007.
Qihai Xu holds an M.S. degree in Organic Chemistry from Lanzhou University and a Ph.D. in Organic Chemistry from Shanghai Institute of Organic Chemistry, CAS. Additionally, they have obtained various certifications in areas such as leadership, management, and soft skills from LinkedIn in 2022.
This person is not in any teams
This person is not in any offices
PharmaBlock Group
PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) is a leading provider of innovative chemistry products & services throughout the pharmaceutical R&D process and commercial production. Its core businesses include: a rationally designed building blocks (BBs) collection, supplying from discovery, to development & commercial; development & manufacturing of RSMs, intermediates & APIs for drug development & commercial. Officially operated in 2008, PharmaBlock has rapidly gained recognition for its outstanding capabilities in the design, synthesis, & supply of novel BBs. It has generated a large and unique collection of high-quality and diverse BBs, which are increasingly adopted by drug hunters to enrich the structure options, improve compound quality, expand patent space and eventually accelerate drug discovery projects. Inspired by the BBs, it has established a powerful drug discovery platform for medicinal chemists to quickly identify hit/lead. The platform includes a set of efficient tools, including but not limited to FBDD, DELT, & Virtual Screening. Following the new molecules advancing from discovery to development, and into the market, the company is committed to a more comprehensive & long-term service to valued customers. In addition to strengthening process R&D capabilities & mfg. capacity to secure the sustainable supply of BBs, the company is providing CDMO solutions of RSMs, key intermediates & APIs. To further realize safe, efficient and green process & mfg., it has developed an advanced chemistry & engineering technology platform, featuring flow chemistry, micropacked bed hydrogenation, catalysis, crystallization, solid state chemistry etc. Over the past years, PharmaBlock has partnered with almost all the top pharmaceutical companies, and hundreds of small to medium-sized biotechs around the world. Our ever changing mission is to support clients to accelerate drug discovery & development, and move the new molecule to commercial in full speed.